Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jun 21, 2023

AI Trading Bot: 15.27% Gains in WAT Stocks - Earnings Report

AI Trading Bot generates Gains of 15.27% for WAT

In the era of machine learning and AI, smart trading tools have emerged to disrupt the investment scene and redefine profitability. These developments, driven by state-of-the-art technology, are revolutionizing the way trading is conducted, and one such powerful tool recently generated a gain of 15.27% for Waters Corporation (WAT), an analytical laboratory instrument and software company.

The innovative AI trading bot employed by WAT has shown exceptional performance, as it leverages both technical analysis (TA) and fundamental analysis (FA) to make effective trading decisions. Its capabilities are particularly powerful in trending down markets where it identifies potential value stocks and accurately forecasts price movements.

Trading bots, such as the one used by WAT, offer an excellent strategy for swing traders, especially those who are beginners. They help new traders understand how the stock market works, particularly when the market is trending downwards. The use of AI trading bots has helped swing traders to navigate through the bear market with ease and efficiency.

In volatile market conditions, the swing trading strategy becomes more important than ever. The AI bot helps traders leverage short-term trends within the overarching bear market, making calculated decisions and executing trades at the right moment.

WAT's AI trading bot combines the principles of technical analysis and fundamental analysis, providing a comprehensive view of the market. TA primarily looks at price movements and trend patterns, while FA includes examining a company's earnings, financial statements, industry health, and many other economic indicators. This blend of TA and FA gives the bot an edge, allowing it to evaluate stocks holistically and take advantage of both short-term price movements and long-term value.

The AI trading bot's performance is made even more impressive when considering the upcoming reported earnings date for WAT, scheduled for August 1, 2023. The results could serve as a key influencing factor for the bot's trading decisions moving forward, as it continues to analyze and learn from the financial data.

The remarkable gains achieved by WAT's AI trading bot highlight the potential of artificial intelligence in the financial sector. It not only demonstrates how AI can improve trading efficiency and profit margins but also offers a glimpse into the future of investment where technology and finance merge seamlessly to provide the best results. As more companies start adopting these advanced tools, the landscape of trading and investment is set to evolve exponentially.

Related Ticker: WAT

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


WAT sees MACD Histogram just turned negative

WAT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 32 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for WAT moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 19 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 71 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

WAT broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on WAT as a result. In 58 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 173 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

The Aroon Indicator entered an Uptrend today. In 125 of 192 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.864) is normal, around the industry mean (72.578). P/E Ratio (112.137) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.78B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -3%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 49%. QUCY experienced the highest price growth at 9%, while BNR experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 59
Price Growth Rating: 45
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
WAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis

Industry MedicalSpecialties

Industry
Medical Specialties
Address
34 Maple Street
Phone
+1 508 478-2000
Employees
7900
Web
https://www.waters.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.
AI Trading Bot: 15.27% Gains in WAT Stocks - Earnings Report